Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study – SIMPLICITY
Mauro MJ et al. Leuk Lymphoma, June 2025 - open access publication
Link to full abstract